These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22956654)

  • 1. Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five-component acellular pertussis vaccine or to pertussis disease.
    Alexander F; Matheson M; Fry NK; Labram B; Gorringe AR
    Clin Vaccine Immunol; 2012 Nov; 19(11):1776-83. PubMed ID: 22956654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007.
    Hallander H; Advani A; Alexander F; Gustafsson L; Ljungman M; Pratt C; Hall I; Gorringe AR
    Clin Vaccine Immunol; 2014 Feb; 21(2):165-73. PubMed ID: 24307240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bordetella pertussis isolates in Finland: serotype and fimbrial expression.
    Heikkinen E; Xing DK; Olander RM; Hytönen J; Viljanen MK; Mertsola J; He Q
    BMC Microbiol; 2008 Sep; 8():162. PubMed ID: 18816412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bordetella pertussis isolates in Finland after acellular vaccination: serotype change and biofilm formation.
    Niinikoski V; Barkoff AM; Mertsola J; He Q
    Clin Microbiol Infect; 2024 May; 30(5):683.e1-683.e3. PubMed ID: 38310999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
    Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
    Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
    Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L
    APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.
    Queenan AM; Dowling DJ; Cheng WK; Faé K; Fernandez J; Flynn PJ; Joshi S; Brightman SE; Ramirez J; Serroyen J; Wiertsema S; Fortanier A; van den Dobbelsteen G; Levy O; Poolman J
    Vaccine; 2019 Jan; 37(1):80-89. PubMed ID: 30478007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bordetella pertussis fimbriae (Fim): relevance for vaccines.
    Gorringe AR; Vaughan TE
    Expert Rev Vaccines; 2014 Oct; 13(10):1205-14. PubMed ID: 25102891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of antibodies against fimbria type 3 (Fim3) is useful diagnostic assay for pertussis.
    Oguchi K; Miyata A; Kazuyama Y; Noda A; Suzuki E; Watanabe M; Nakayama T
    J Infect Chemother; 2015 Sep; 21(9):639-46. PubMed ID: 26134278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological differences between FIM2 and FIM3 fimbriae of Bordetella pertussis: not just the serotype.
    Matczak S; Bouchez V; Leroux P; Douché T; Collinet N; Landier A; Gianetto QG; Guillot S; Chamot-Rooke J; Hasan M; Matondo M; Brisse S; Toubiana J
    Microbes Infect; 2023; 25(7):105152. PubMed ID: 37245862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
    Barkoff AM; Guiso N; Guillot S; Xing D; Markey K; Berbers G; Mertsola J; He Q
    J Immunol Methods; 2014 Jun; 408():142-8. PubMed ID: 24925807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs.
    Hallander HO; Advani A; Donnelly D; Gustafsson L; Carlsson RM
    J Clin Microbiol; 2005 Jun; 43(6):2856-65. PubMed ID: 15956409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis.
    Xu Y; Wang Y; Tan Y; Zhang H; Wu L; Wang L; Hou Q; Zhang S
    BMC Microbiol; 2009 Dec; 9():274. PubMed ID: 20040101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the fim2 and fim3 fimbrial subunit genes of Bordetella bronchiseptica: roles of Fim2 and Fim3 fimbriae and flagella in adhesion.
    Savelkoul PH; de Kerf DP; Willems RJ; Mooi FR; van der Zeijst BA; Gaastra W
    Infect Immun; 1996 Dec; 64(12):5098-105. PubMed ID: 8945552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling anti-pertussis toxin IgG antibody decay following primary and preschool vaccination with an acellular pertussis vaccine in UK subjects using a modified oral fluid assay.
    Fry NK; Litt DJ; Duncan J; Vaghji L; Warrener L; Samuel D; Andrews N; Harnden A; Harrison TG
    J Med Microbiol; 2013 Sep; 62(Pt 9):1281-1289. PubMed ID: 23722435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection.
    Olivera N; Castuma CE; Hozbor D; Gaillard ME; Rumbo M; Gómez RM
    Biomed Res Int; 2014; 2014():421486. PubMed ID: 24982881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody Specificity Following a Recent
    Raeven RHM; van der Maas L; Pennings JLA; Fuursted K; Jørgensen CS; van Riet E; Metz B; Kersten GFA; Dalby T
    Front Immunol; 2019; 10():1364. PubMed ID: 31275314
    [No Abstract]   [Full Text] [Related]  

  • 18. Epitope mapping the Fim2 and Fim3 proteins of Bordetella pertussis with sera from patients infected with or vaccinated against whooping cough.
    Williamson P; Matthews R
    FEMS Immunol Med Microbiol; 1996 Feb; 13(2):169-78. PubMed ID: 8731026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertactin-deficient
    Barkoff AM; Mertsola J; Pierard D; Dalby T; Hoegh SV; Guillot S; Stefanelli P; van Gent M; Berbers G; Vestrheim D; Greve-Isdahl M; Wehlin L; Ljungman M; Fry NK; Markey K; He Q
    Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study.
    Xing D; Wirsing von König CH; Newland P; Riffelmann M; Meade BD; Corbel M; Gaines-Das R
    Clin Vaccine Immunol; 2009 Mar; 16(3):303-11. PubMed ID: 19109448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.